Presper Financial Architects LLC Buys New Position in Johnson & Johnson $JNJ

Key Points

• Presper Financial Architects LLC acquired 1,820 shares of Johnson & Johnson, amounting to approximately $278,000, during the 2nd quarter, indicating institutional interest in the stock.
• Johnson & Johnson reported a 2.1% increase in stock price and noted quarterly earnings of $2.77 EPS, surpassing estimates and showing a year-over-year revenue growth of 5.8%.
• In recent analyst activity, Guggenheim upgraded Johnson & Johnson from "neutral" to "buy", raising its price target from $167 to $206, reflecting increased optimism in the stock's performance.

Presper Financial Architects LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,820 shares of the company's stock, valued at approximately $278,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the 1st quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 2.1%

Shares of NYSE:JNJ opened at $185.40 on Wednesday. The business's 50 day simple moving average is $175.11 and its two-hundred day simple moving average is $162.34. The firm has a market cap of $446.51 billion, a P/E ratio of 19.83, a PEG ratio of 2.31 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $185.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on JNJ shares. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Bank of America upped their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Morgan Stanley upped their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $181.40.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.